2-溴-1-(2,3-二氢-1,4-苯并氧)乙酮 | 19815-97-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 2-溴-1-(2,3-二氢-1,4-苯并氧)乙酮
• 英文名称: 2-bromo-1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethanone
• 英文别名: 2-bromo-1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethan-1-one；2-bromo-1-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-ethanone；2-bromo-1-(2,3-dihydro-1,4-benzodioxin-5-yl)ethanone
• CAS: 19815-97-5
• 化学式: C₁₀H₉BrO₃
• 分子量: 257.084
• InChiKey: BSROYFIAEPSLCT-UHFFFAOYSA-N

物化性质

• 熔点：
  71 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  C
• 危险类别码：
  R34
• 海关编码：
  2932999099
• 安全说明：
  S26,S36/37/39,S45

SDS

Name:	2-Bromo-1-(2 3-dihydro-1 4-benzodioxin-5-yl)-1-ethanone 97% Material Safety Data Sheet
Synonym:	None Known
CAS:	19815-97-5

Section 1 - Chemical Product MSDS Name:2-Bromo-1-(2 3-dihydro-1 4-benzodioxin-5-yl)-1-ethanone 97% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
19815-97-5	2-Bromo-1-(2,3-dihydro-1,4-benzodioxin	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately. Do NOT allow victim to rub eyes or keep eyes closed.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing.
Keep container tightly closed. Do not ingest or inhale. Use only in a chemical fume hood. Discard contaminated shoes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 19815-97-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 99 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H9BrO3
Molecular Weight: 257.08

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
This material should not be used or stored in conditions of high (or highly fluctuating) temperature or be exposed to any possible source of ignition. Exposure of the material to direct sunlight or the air should be kept to a minimum.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Amines, bases, oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 19815-97-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Bromo-1-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-ethanone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 19815-97-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 19815-97-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 19815-97-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-1-(2,3-二氢-1,4-苯并氧)乙酮 在 potassium carbonate 、 氯化铵 、 锌 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethanone
  参考文献：
  名称：

  芳基丙烯酰基O-烷基和O-苯基衍生物转化为酮

  摘要：

  摘要 在乙醇中用 2-3 当量 Zn 和 1-2 当量 NH4Cl 处理芳基酰（α-羟基酮）O-烷基和 O-苯基衍生物，回流 20-120 分钟，得到相应的酮，收率极好. 此外，α,β-环氧酮可以有效地转化为β-羟基酮，2,2-二烷氧基-1-苯基酮也可以脱烷氧基化为1-苯基酮。

  DOI：

  10.1080/00397910600978564
• 作为产物：
  描述：

  1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethanone 在 溴 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以3 g的产率得到2-溴-1-(2,3-二氢-1,4-苯并氧)乙酮
  参考文献：
  名称：

  4-（吡啶-4-氧基）-3-（3,3-二氟环丁基）-吡唑衍生物的合成和生物学评估，该衍生物为新型有效的转化生长因子-β1型受体抑制剂。

  摘要：

  抑制转化生长因子β（TGF-β）1型受体（ALK5）提供了一种治疗纤维化疾病和恶性肿瘤的可行方法。在这项研究中，我们设计并合成了一系列新的4-（吡啶-4-氧基）-3-（3,3-二氟环丁基）-吡唑衍生物，并作为TGF-β1型受体抑制剂进行了生物学评估。最有效的化合物15r抑制ALK5酶和NIH3T3细胞的活力，IC50值分别为44和42.5 nM。与LY-3200882相比，化合物15r还具有更好的口服血浆暴露和出色的生物利用度，并且在CT26异种移植小鼠模型中体内抑制了65.7％的肿瘤生长。

  DOI：

  10.1016/j.ejmech.2020.112354

文献信息

• [EN] IMIDAZOPYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS IMIDAZOPYRIDINES
  申请人：PROXIMAGEN LTD

  公开号：WO2010064020A1

  公开（公告）日：2010-06-10

  The invention relates to compounds of formula (I): and their pharmaceutically acceptable salts and solvates, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.

  这项发明涉及式(I)的化合物及其药学上可接受的盐和溶剂化合物，这些化合物是SSAO活性的抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物治疗或预防抑制SSAO活性有益的医疗状况，如炎症性疾病和免疫紊乱。
• Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1
  作者：Espérance Moine、Isabelle Dimier-Poisson、Cécile Enguehard-Gueiffier、Cédric Logé、Mélanie Pénichon、Nathalie Moiré、Claire Delehouzé、Béatrice Foll-Josselin、Sandrine Ruchaud、Stéphane Bach、Alain Gueiffier、Françoise Debierre-Grockiego、Caroline Denevault-Sabourin

  DOI：10.1016/j.ejmech.2015.10.004

  日期：2015.11

  Using a structure-based design approach, we have developed a new series of imidazo[1,2-b]pyridazines, targeting the calcium-dependent protein kinase-1 (CDPK1) from Toxoplasma gondii. Twenty derivatives were thus synthesized. Structure-activity relationships and docking studies confirmed the binding mode of these inhibitors within the ATP binding pocket of TgCDPK1. Two lead compounds (16a and 16f) were

  使用基于结构的设计方法，我们开发了一系列新的咪唑并[1,2- b ]哒嗪类药物，靶向弓形虫的钙依赖性蛋白激酶-1（CDPK1）。由此合成了二十种衍生物。结构活性关系和对接研究证实了这些抑制剂在Tg CDPK1的ATP结合口袋中的结合模式。然后鉴定了两种先导化合物（16a和16f），它们能够在低纳摩尔浓度下阻断Tg CDPK1的酶促活性，并且对一组哺乳动物激酶具有良好的选择性。这些抑制剂的潜力已在体外T上得到证实。刚地生长，EC 50值分别为100 nM和70 nM。这些最佳候选物还显示出对哺乳动物细胞的低毒性，并被选择用于急性弓形虫病小鼠模型的进一步体内研究。
• Trithiocarbonates—Exploration of a new head group for HDAC inhibitors
  作者：Florian Dehmel、Thomas Ciossek、Thomas Maier、Steffen Weinbrenner、Beate Schmidt、Martin Zoche、Thomas Beckers

  DOI：10.1016/j.bmcl.2007.06.063

  日期：2007.9

  class I/II enzymes is a new, promising approach for cancer therapy. In the present study, we disclose a new structural class of HDAC inhibitors with the trithiocarbonate motif. A clear structure-activity-relationship was obtained for the cap-linker motif and the putative Zn(2+) complexing head group. Selected analogs display potent inhibition of HDAC enzymatic activity and a cellular potency comparable

  抑制组蛋白脱乙酰基酶I / II类酶是一种新的，有前途的癌症治疗方法。在本研究中，我们公开了具有三硫代碳酸酯基序的HDAC抑制剂的新结构类别。明确的结构-活性-关系获得了帽连接基序和假定的Zn（2+）络合头基。所选类似物显示出对HDAC酶活性的有效抑制作用，并且具有与最近被批准用于治疗晚期皮肤T细胞淋巴瘤的辛二酰苯胺异羟肟酸（SAHA）相当的细胞效价。
• 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
  申请人：Himmelsbach Frank

  公开号：US20080255159A1

  公开（公告）日：2008-10-16

  The present invention relates to substituted xanthines of general formula wherein R 1 to R 3 are defined as in claims 1 to 16 , the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及一般式的取代黄嘌呤，其中R1至R3的定义如权利要求1至16所述，其互变异构体、立体异构体、混合物、前药和盐具有有价值的药理特性，特别是对酶二肽基肽酶-IV（DPP-IV）的抑制作用。
• 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040097510A1

  公开（公告）日：2004-05-20

  The present invention relates to substituted xanthines of general formula 1 wherein R 1 to R 3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPI-IV).

  本发明涉及一般式1的取代黄嘌呤，其中R1至R3的定义如权利要求1至16所述，其互变异构体、立体异构体、混合物、前药及其盐具有有价值的药理学特性，特别是对酶二肽基肽酶-IV（DPI-IV）的抑制作用。